Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has said that its scientists continue to carry out multiple psychedelic-based clinical research trials, adding to the company's large and growing proprietary dataset critical to informing future drug development.
To date, Braxia Scientific has compiled comprehensive health data from administering more than 5,200 ketamine treatments at its network of clinics.
Additionally, Braxia Scientific's researchers have published 43 ketamine-related manuscripts in peer-reviewed biomedical journals, and the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly-owned Braxia subsidiary, has established a growing database with key clinical outcomes for an ongoing clinical trial evaluating psilocybin-assisted therapy.
READ: Braxia Scientific closes C$3M private placement to fund expansion of clinics and investments
"We are tremendously proud of our research team, which includes three individuals ranked among the world's top 20 experts in depression, mood disorders, and ketamine research," said Roger McIntyre, CEO of Braxia Scientific. "With our unmatched human capital, well-established clinical infrastructure, and large proprietary health database we believe Braxia Scientific has a distinct competitive advantage among the leading groups endeavoring to develop new psychedelic treatments.”
He added: "With this expertise and data, we are well-positioned to enhance our intellectual property, including our work to identify and develop new chemical entities, while providing patients with access to new pathways to treat their mental health disorders."
Building on management's extensive clinical expertise, the company has expanded the necessary infrastructure to provide innovative interventions that include ketamine, psilocybin, and other potential future psychedelics that become available.
The Toronto-based company said that it also continues to exhibit itself as a leader in the psychedelics industry, establishing treatment protocols and best practice guidelines, including for innovative potential therapies, such as psilocybin.
Braxia Scientific’s leadership is illustrated by the publication by the American Journal of Psychiatry of the International Expert Opinion and Implementation Guidance, led by Braxia Scientific's leaders, which outlines ketamine and esketamine treatment parameters and sets the standard for the clinical implementation of rapid-acting treatments in persons with treatment-resistant depression.
Contact Ritika at ritika@proactiveinvestors.com